$PCVX: Vaxcyte Just Swept the Year's Biggest Vaccine Readout. Pricing the 53% Premarket Repricing
VAX-31 met every primary endpoint in its pivotal adult Phase 3 against Prevnar 20 and Capvaxive, and the stock gapped to a record. The share math, the serotype 3 fine print, the cash clock, and scenario zones for all four paths from here.
Before the opening bell this morning, Vaxcyte (Nasdaq: PCVX) released the single most consequential dataset in its history: topline results from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine. The company says the shot met every prespecified primary immunogenicity endpoint, in every age group studied, against both of the incumbent vaccines it was tested against. By 7:45 a.m., the stock was trading around $86.44 in the premarket, up roughly 53% from Friday's $56.48 close, and well above its prior 52-week high of $65.
To understand why the reaction is this violent, you need the scar tissue. On March 31, 2025, Vaxcyte reported infant Phase 2 data on its earlier 24-valent candidate that the company called positive but the Street read as a miss, with 20 of 24 serotypes meeting the target criteria. The stock went from $69.46 to $37.76 in a single session, a 45.6% one-day loss, and spent the next eighteen months rebuilding credibility one readout at a time. Since then, every Vaxcyte print has been handicapped with that day in mind. OPUS-1 was the big one: a 4,047-participant, roughly 30-site U.S. trial, run head-to-head against Pfizer's Prevnar 20 and Merck's Capvaxive, the two vaccines that define the standard of care. A second stumble would have put the whole franchise thesis in question. Instead, the company reported a sweep.
The numbers behind the headline: all 28 VAX-31 serotypes that overlap with Prevnar 20 and/or Capvaxive met the prespecified noninferiority criteria in adults 50 and older. The three serotypes unique to VAX-31, plus cross-reactive serotype 20B, didn't just match the comparators; they met a formal superiority criterion with multiplicity adjustment. In the 18-to-49 immunobridging cohort, all 321 serotype comparisons met noninferiority. Safety and tolerability came in similar to both comparators. For a vaccine whose entire commercial argument is "broadest coverage, no compromises," it is close to the best realistic outcome the protocol allowed.
The prize this aims at is one of the largest in all of vaccines. Pfizer's Prevnar franchise did $6.5 billion in revenue in 2025, roughly a tenth of Pfizer's entire top line. Merck's Capvaxive, the 21-valent adult shot approved in mid-2024, pulled in $530 million across its first four quarters, and analysts have marked peak estimates toward $1.8 billion. The CDC's advisory committee widened the funnel in late 2024 by lowering the routine adult vaccination age from 65 to 50. Vaxcyte's pitch is that the incumbents force a tradeoff, with Prevnar 20 covering one set of circulating serotypes and Capvaxive another, while VAX-31 covers what the company estimates is approximately 95% of invasive pneumococcal disease in U.S. adults 50 and up. Today's data is the first pivotal evidence that the broadest shot doesn't pay for its breadth with weaker responses.
So the binary resolved, and it resolved up. But this morning's premarket print values Vaxcyte at roughly $12.9 billion, for a company with no product revenue, a licensure application that is still years out, and a readout that, on close inspection, contains exactly one piece of fine print the bears will organize around. The questions that matter now: what does $86 actually assume, how long is the road from here to a licensed product, what does the cash clock look like against a burn rate north of a billion dollars a year, and where are the zones if the next readouts confirm or complicate today's sweep? That is what the rest of this briefing prices out.
Get the next briefing free in your inbox before the market prices it in: Join AlphaBriefing
The rest of this briefing is for paid members: the SEC-verified share count and what $86 implies against the incumbents' revenue, the serotype 3 fine print nobody is reading yet, the cash-runway math against a First Half 2028 filing, the full catalyst calendar through launch, and scenario-by-scenario price zones for all four paths from here.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.